http://www.morgans.com.au/Blog/2014/February/Admedus.aspx
Not even Scott Power can pick the market, so we aint got a hope in hell picking it either
Admedus
Scott Power
By Scott Power, 03 February 2014, 8:33 AM
Senior Analyst
Sectors Covered: Healthcare, Life Science, Telecommunications, Technology and Media
Today's big news in the healthcare space is from Admedus (formerly Allied Healthcare).
Admedus (AHZ) has successfully hit its primary endpoint for its Phase 1 Herpes Simplex Virus (HSV-2) vaccine trial. In addition, the study has also shown that the vaccine was able to generate a T-cell response. Once further analysis is completed the program will be taken into a second clinical study in patients infected with the Herpes virus.
The market should respond favourably to today's announcement.
The next major milestone we are looking for is US FDA approval for its CardioCel product expected mid-year.
We retain our Add recommendation with a share price target of $0.20.
positive news, page-6
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.550(5.12%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.73 | $10.73 | $10.15 | $109.7K | 10.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 490 | $10.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 911 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |